Table 4.
Reported gender affirming hormone therapy (GAHT) use by cohort, study arm, and starting period.
| Reported GAHT Use (TGW) | Reported GAHT Use (MSM) | |||||
|---|---|---|---|---|---|---|
| GAHT Reported at Baseline | GAHT Initiated During Follow-up | Total GAHT Use Reported | GAHT Reported at Baseline | GAHT Initiated During Follow-up | Total GAHT Use Reported | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Participants who self-reported any type of GAHT Hormone therapy type 1 | 249/570 (43.7) | 81/570 (14.2) | 330/570 (57.9) | 7/3996 (0.2) | 25/3996 (0.6) | 32/3996 (0.8) |
| Antiandrogens | 202/249 (81.1) | 50/81 (61.7) | 252/330 (76.4) | 5/7 (71.4) | 16/25 (64.0) | 21/32 (65.6) |
| Estrogens | 239/249 (96.0) | 71/81 (87.7) | 310/330 (93.9) | 6/7 (85.7) | 20/25 (80.0) | 26/32 (81.3) |
| Progestogens | 91/249 (36.5) | 26/81 (32.1) | 117/330 (35.5) | 2/7 (28.6) | 9/25 (36.0) | 11/32 (34.4) |
CAB-LA: Cabotegravir; GAHT: gender affirming hormone therapy; MSM: men who have sex with men; TDF/FTC: Tenofovir disoproxil fumarate/emtricitabine; TGW: transgender women.
1
Numerator refers to the number of participants who reported each hormone therapy regimens; denominators refer to the number of participants who reported GAHT use at baseline or during follow-up.